NCT04264442Phase 2Terminated

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Study sponsor: Fulcrum Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-11-07Actual
Enrollment · participants76Actual
Source updated2025-09-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview